Business
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p<0.0001) across all dosing groups (n=23) support the proposed mechanism of beta cell restorationBest response observed in prespecified, beta-cell deficient patients on one or more antihyperglycemic agents at baseline, a
About this update from Biomea Fusion, Inc.
[{"type":"image","alt":"Biomea Fusion, Inc.","displaySize":"","headline":null,"caption":"Biomea Fusion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gkukhuOJZCy6sOBr1Udv6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3","width":300,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib","length":201,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":201,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p<0.0001) across all dosing groups (n=23) support the proposed mechanism of beta cell restoration","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Best response observed in prespecified, beta-cell deficient patients on one or more antihyperglycemic agents at baseline, achieving a statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022), after only 12 weeks of 100 mg once daily icovamenib","length":283,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical in vivo experiments indicated that icovamenib enhanced the responsiveness of human islets to GLP-1-based medicines, consistent with the increase in expression levels (transcript and protein) of both the GLP-1 receptor and intracellular insulin","length":255,"tagName":"p"}]},{"val":[{"type":"text","content":"Severe Insulin Deficient Diabetes represents an underserved patient population within type 2 diabetes and is estimated to be over 100 million people worldwide.","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":875,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of preclinical and clinical data from studies assessing icovamen...